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Introduction
The growth and survival of cancer cells in the context of many cell-intrinsic and cell-extrinsic stresses, such as 
nutrient deprivation or hypoxia, relies upon balanced protein synthesis, folding, quality control, and degrada-
tion. The accelerated protein synthesis rate and the rapid cell cycle of these transformed cells make them even 
more dependent on correct protein homeostasis. This observation has been explored in a therapeutic context 
where proteasome inhibitors, which drive cancer cells into a state of proteotoxic stress, have been successful in 
The endoplasmic reticulum (ER) of cancer cells needs to adapt to the enhanced proteotoxic 
stress associated with the accumulation of unfolded, misfolded, and transformation-associated 
proteins. One way by which tumors thrive in the context of ER stress is by promoting ER-associated 
degradation (ERAD), although the mechanisms are poorly understood. Here, we show that the 
small p97/VCP-interacting protein (SVIP), an endogenous inhibitor of ERAD, undergoes DNA 
hypermethylation–associated silencing in tumorigenesis to achieve this goal. SVIP exhibits tumor 
suppressor features and its recovery is associated with increased ER stress and growth inhibition. 
Proteomic and metabolomic analyses show that cancer cells with epigenetic loss of SVIP are 
depleted in mitochondrial enzymes and oxidative respiration activity. This phenotype is reverted 
upon SVIP restoration. The dependence of SVIP-hypermethylated cancer cells on aerobic glycolysis 
and glucose was also associated with sensitivity to an inhibitor of the glucose transporter GLUT1. 
This could be relevant to the management of tumors carrying SVIP epigenetic loss, because these 
occur in high-risk patients who manifest poor clinical outcomes. Overall, our study provides insights 
into how epigenetics helps deal with ER stress and how SVIP epigenetic loss in cancer may be 
amenable to therapies that target glucose transporters.
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treating certain hematologic malignancies (1). The endoplasmic reticulum (ER) is a critical organelle in protein 
homeostasis that, in addition to lipid synthesis and distribution, and calcium regulation (2), controls protein 
synthesis, folding, modification, and transport. In this regard, nearly one-third of all cellular proteins are synthe-
sized, folded, and modified in the ER (3). If, at steady state, the ER is able to maintain protein homeostasis, the 
high protein synthesis rate and the increased number of misfolded proteins that occur in cancer cells can trigger 
an ER stress response that will eventually lead to apoptosis (3). Thus, tumors must adapt their ER machinery to 
handle this proteotoxic stress if  they are to survive and keep growing. The main ER stress adaptive mechanisms 
are the unfolded protein response (UPR) and the ER-associated degradation (ERAD) pathways (4). Both of  
them lead to global protein attenuation and the clearance of misfolded proteins in the ER to ameliorate the 
proteotoxic stress. The UPR network in the context of human tumors has been widely studied (5), and here we 
focus more on the ERAD pathway, which is less well understood at the molecular level.
ERAD ensures protein quality and quantity by guiding misfolded or unassembled proteins from the ER 
to their degradation by the ubiquitin-proteasome system (UPS) (6). ERAD is also used to regulate the exces-
sive abundance of  mature proteins in response to shifts in cellular requirements (6). The ERAD substrates 
are retrotranslocated across the ER membrane into the cytosol through the AAA-ATPase valosin-contain-
ing protein (VCP, also known as p97) and degraded by the 26S proteasome (6). The key role of  VCP in 
protein homeostasis is highlighted by the observation that its specific inhibitors lead to irresolvable proteo-
toxic stress associated with antitumor activity (7–9), even in cancer models where proteasome inhibitors are 
inactive (7), a finding that prompted their further evaluation in clinical trials (ClinicalTrials.gov identifiers: 
NCT02243917 and NCT02223598). Thus, the activity of  VCP in cells must be tightly regulated. In this 
regard, there are 3 proteins that possess a VCP-interacting motif  (VIM) (10) that allows them to bind direct-
ly to VCP: E3 ubiquitin-protein ligase AMFR (also known as tumor autocrine motility factor receptor, or 
gp78) (11); selenoprotein S (also known as SELENOS or VIMP) (12), which acts as a recruitment factor 
for E3 ubiquitin-protein ligase synoviolin (SYVN1 or HRD1) (13); and small VCP/p97-interacting protein 
(SVIP). AMFR and SELENOS-SYVN1 promote ERAD due to their catalytic activity and interaction with 
DERL proteins (11), while SVIP acts as an endogenous inhibitor of  this process (14).
We wondered about the existence of  cancer-specific defects in VCP and its main interactor proteins that 
could explain how tumoral ER can maintain protein homeostasis to overcome cell death. We found that SVIP 
behaves as a tumor suppressor gene that undergoes epigenetic-associated transcriptional silencing in a wide 
range of  human tumors. SVIP restoration in deficient cells blocks ERAD, promotes ER stress, and induces a 
metabolic shift from aerobic glycolysis to mitochondrial respiration. Our findings thus indicate a role for SVIP 
loss as an adaptive mechanism in human tumors to thrive in the ER stress–prone environment of  cancer cells.
Results
Characterization of  SVIP CpG island promoter hypermethylation–associated transcriptional silencing in cancer cells. To 
find putative genetic and epigenetic changes in the VCP-mediated ERAD pathway composed of  VCP, SELE-
NOS, SYVN1, SVIP, AMFR, and DERLIN1-3 in human tumors, we first data-mined a set of  1,001 human 
cancer cell lines in which we had recently obtained the exome sequence, transcriptome, gene copy number, 
and DNA methylation landscapes (15). The status of  DERLIN1-3 in this collection of  samples has previously 
been studied (16) and is not discussed further here. The available genomic data did not show the existence of  
VCP, SELENOS, SYVN1, SVIP, and AMFR mutations, deletions, or amplifications in the analyzed cell lines 
(Supplemental Dataset 1; supplemental material available online with this article; https://doi.org/10.1172/
jci.insight.125888DS1). Although no genetic lesions were observed in the aforementioned genes, transcrip-
tional silencing by promoter CpG island hypermethylation is an alternative mechanism by which gene inac-
tivation in transformed cells may be achieved (17–19). VCP/p97, SELENOS, SYVN1, and AMFR/GP78 
promoter-associated CpG islands were unmethylated in the analyzed cell lines (Supplemental Dataset 1). 
However, the SVIP promoter CpG island was methylated in 50% (19 of  38) of  head and neck cancer cell lines 
(Figure 1A and Supplemental Dataset 1). Apart from head and neck tumors, the SVIP promoter CpG island 
was most often found to be unmethylated in the other cancer types, with the exception of  esophageal (8 of  35, 
23%) and cervical (3 of  14, 21%) cancers, and hematological malignancies (22 of  154, 14%), particularly B 
cell lymphoma (15 of  45, 33%) (Figure 1A and Supplemental Dataset 1). Data-mining of  the available tran-
scriptome profiles in this cancer cell line collection (15) showed SVIP hypermethylation to be associated with 
downregulation of  the mRNA (Figure 1B and Supplemental Figure 1A). The SVIP promoter CpG island was 
found to be unmethylated in all the normal human tissues tested (Supplemental Dataset 2).
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Having observed the SVIP CpG island methylation profiles described above, we interrogated in detail 
the link with the loss of  the SVIP gene at the RNA and protein levels. We performed bisulfite genomic 
sequencing of  multiple clones in head and neck (BB30-HNC, BHY, Ca9-22, and LB771-HNC), esophageal 
(COLO-680N, KYSE-180, and OACM 5.1C), and cervical (Ca-Ski, HeLa, and SW756) cancer cell lines 
using oligonucleotides that encompassed the transcription start site–associated CpG island. We observed 
that the 5′-end CpG island of  SVIP in the BB30-HNC, BHY, COLO-680N, KYSE-180, and Ca-Ski cell 
lines was hypermethylated in comparison with normal tissues (Figure 1C and Supplemental Figure 1B), 
whereas the Ca9-22, LB771-HNC, OACM 5.1C, HeLa, and SW756 and cells were unmethylated (Figure 
1C and Supplemental Figure 1B). These results mimicked DNA methylation profiles determined using 
the microarray approach (Figure 1D and Supplemental Figure 1C). The SVIP-hypermethylated cell lines 
BB30-HNC, BHY, COLO-680N, KYSE-180, and Ca-Ski minimally expressed the SVIP RNA transcript 
and protein, as determined by quantitative PCR (qPCR) and Western blot, respectively (Figure 1E and 
Supplemental Figure 1D). Expression of  SVIP RNA and protein was observed in the unmethylated cell 
lines (Figure 1E and Supplemental Figure 1D). Treatment of  the SVIP-methylated cell lines with the DNA 
methylation inhibitor 5-aza-2′-deoxycytidine restored SVIP expression (Figure 1F and Supplemental Fig-
ure 1E). In summary, these data indicate that tumor-specific promoter CpG island hypermethylation–asso-
ciated silencing of  the SVIP gene takes place in cancer cells.
SVIP exhibits tumor suppressor features. Once we had shown the presence of  SVIP CpG island hypermeth-
ylation–associated loss in cancer cell lines, we assessed its role in tumor growth in vitro and in vivo. We 
first studied the effect of  the recovery of  SVIP expression in epigenetically silenced cells. Upon the efficient 
transfection of  SVIP in the hypermethylated BB30-HNC cells, validated by qPCR and Western blot (Figure 
2A), we found a significant reduction in cellular growth measured by the sulforhodamine B (SRB) assay in 
comparison with empty vector–transfected cells (Figure 2B). We extended the model to a second head and 
neck cancer cell line, one cervical cancer cell line, and two esophageal cancer cell lines where we also found 
that the efficient recovery of  SVIP expression by transfection in the SVIP-hypermethylated BHY, Ca-Ski, 
COLO-680N, and KYSE-180 cells (Supplemental Figure 2A) induced a significant reduction in cell viability 
(Supplemental Figure 2B). We also developed the reverse approach by studying the effect of  SVIP depletion in 
head and neck cancer cells that were unmethylated and expressed the SVIP transcript and protein. Upon effi-
cient short hairpin RNA–mediated (shRNA-mediated) depletion of  SVIP in Ca9-22 cells, validated by qPCR 
and Western blot (Figure 2C), we observed that the reduction of  SVIP levels had growth-promoting features, 
determined by an increased viability in the SRB assay, in comparison with scramble shRNA–treated cells 
(Figure 2D). In this regard, low levels of  SVIP are also associated with high expression of  the proliferation 
marker CCND1 in the Sanger panel of  cancer cell lines (15) (Supplemental Figure 2C).
The in vitro data were then interrogated in an in vivo model. We studied the capacity of  SVIP-transfect-
ed BB30-HNC cells to form subcutaneous tumors in nude mice compared with empty vector–transfected 
cells. The recovery of  SVIP expression in these head and neck tumors decreased their growth in compar-
ison with empty vector–derived tumors, as shown by the continuous measurement of  the tumor volume 
(Figure 2E). Tumor samples obtained at the endpoint of  the experimental model showed that tumors of  
the SVIP-transfected cells weighed less than those measured in empty vector–transfected cells (Figure 2E). 
Overall, our observations indicate that SVIP has tumor suppressor–like properties in cancer cells.
SVIP promotes ER stress, rendering cancer sells sensitive to SERCA inhibition. Once we had determined the 
epigenetic silencing of  SVIP in cancer cells and its role in promoting tumor growth, we turned our attention 
to the effect of  SVIP expression on ER stress. In this regard, it has previously been shown that prolonged 
ER stress, usually associated with the accumulation of  misfolded protein in the ER, is associated with SVIP 
overexpression (14, 20, 21). For this reason, we assessed the cellular and molecular phenotypes of  the ER 
in our experimental model. Using transmission electron microscopy (TEM), we found that the restoration 
of  SVIP expression in the hypermethylated BB30-HNC, BHY, and Ca-Ski cells induced the formation of  
intracellular vacuoles derived from the ER, indicated by the presence of  attached ribosomes, in comparison 
with what occurred in empty vector–transfected cells (Figure 3A and Supplemental Figure 3A). Similar 
vacuolation and ER dilation has already been described as a consequence of  SVIP transfection in other 
models (22). These vacuoles are thought to be caused by the accumulation of  misfolded proteins (23). Most 
importantly, we found that the recovery of  SVIP expression in the hypermethylated head and neck (BB30-
HNC and BHY) and cervical (Ca-Ski) cancer cells provoked not only cell vacuolation, but also overall 
upregulation of  proteins associated with ER stress (Figure 3B and Supplemental Figure 3B). This was the 
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case for those proteins involved in the unfolded protein response (UPR), such as IRE1α (total and phos-
phorylated), PERK, BIP, and phosphorylated eIF2α, and those involved in protein folding, such as PDI 
and ERO1-Lα (Figure 3B and Supplemental Figure 3B). In agreement with the observed phenotype, the 
shRNA-mediated depletion of  SVIP in the unmethylated Ca9-22 induced the opposite effect: the downreg-
ulation of  the described UPR and protein folding markers (Figure 3B). Data mining of  the Sanger panel of  
cancer cell lines further confirmed that SVIP hypermethylation was associated with the overexpression of  
other ER stress markers such as the UPR protein XBP1 and the ERAD protein DERL3 (Supplemental Fig-
ure 3C). SVIP restoration did not affect Sel1L and Hrd1 levels (Supplemental Figure 3D). Autophagy was 
also induced upon SVIP transfection in BB30-HNC cells, as demonstrated by the presence of  double-mem-
brane autophagosomes (Figure 3A) and the induction of  the autophagy-related proteins BECLIN1 and 
p62, in addition to the cleavage of  LC3B (Figure 3C). The recovery of  SVIP expression in these cancer cells 
was not associated with the formation of  apoptotic bodies (Figure 3A), the cleavage of  the proapoptotic 
proteins PARP and caspase 3 (Figure 3D), or the induction of  cell cycle arrest or senesce determined by 
Figure 1. Transcriptional silencing of SVIP by promoter CpG island hypermethylation in human cancer cells. (A) Percentage of SVIP methylated cell lines 
in the Sanger panel of cancer cell lines by tumor type. Cell lines were considered methylated if the average of β values of interrogated CpGs was equal to 
or higher than 0.66. (B) SVIP promoter CpG island hypermethylation is significantly associated with loss of the SVIP transcript in the Sanger cancer cell 
lines (n = 862). (C) Bisulfite genomic sequencing of SVIP promoter CpG island in head and neck cancer cell lines, normal lymphocytes, and normal skin. 
CpG dinucleotides are represented as short vertical lines; the transcription start site (TSS) is represented as a long black arrow. Single clones are shown for 
each sample. Presence of an unmethylated or methylated cytosine is indicated by a white or black square, respectively. (D) DNA methylation profile of the 
CpG island promoter for the SVIP gene analyzed by the 450K DNA methylation microarray. Single CpG absolute methylation levels (0–1) are shown. Green, 
unmethylated; red, methylated. Data from the 4 head and neck cancer cell lines, normal lymphocytes, and normal skin are shown. (E) SVIP expression lev-
els in head and neck cancer cell lines determined by qPCR (data shown represent the mean biological triplicates) (left) and Western blot (right). (F) Expres-
sion of the SVIP RNA transcript (data shown represent the mean of biological triplicates) (left) and protein (right) was restored in the SVIP epigenetically 
silenced BB30-HNC and BHY cells by treating with the demethylating drug 5-aza-2′-deoxycytidine (AZA). qPCRs were analyzed using a 2-tailed Student’s t 
test. *P < 0.05; **P < 0.01; ***P < 0.001.
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p21 immunoblotting (Figure 3E) and the senescence-associated β-galactosidase assay (Supplemental Figure 
3E), respectively. Thus, these data suggest that SVIP epigenetic silencing could be used in cancer cells as 
a way of  reducing ER stress and maintaining the protein homeostasis that is necessary for their survival.
Pharmacological agents that induce ER stress have been found to exhibit antitumor activity. Thus, we also 
examined whether cells that experience enhanced ER stress upon SVIP transfection can be pushed over the 
edge by these drugs because they can no longer cope with the massive ER stress levels. We did not detect any 
Figure 2. SVIP features tumor suppressor activities in vitro and in vivo. (A) Efficient restoration of SVIP expression 
upon transfection in BB30-HNC cells according to qPCR (left) and Western blot (right). qPCR values are represented as 
mean of biological triplicates and analyzed using a 2-tailed Student’s t test. (B) SRB assay shows that SVIP trans-
fection reduces viability of BB30-HNC cells. This graph is representative of 3 independent experiments. Each data 
point represents mean ± SD. Statistical differences were determined using a 2-tailed Student’s t test at the 144-hour 
time point. (C) Efficient shRNA-mediated depletion of SVIP according to qPCR (left) and Western blot (right) in the 
unmethylated Ca9-22 head and neck cancer cell line. qPCR values are represented as mean of biological triplicates and 
analyzed using a 2-tailed Student’s t test. Two shRNA clones are shown. (D) SRB assay shows that SVIP shRNA-medi-
ated depletion increases viability of Ca9-22 cells. This graph is representative of 3 independent experiments. Each data 
point represents mean ± SD. Statistical differences were determined using a 2-tailed Student’s t test at the 144-hour 
time point. (E) Empty vector–transfected (EV-transfected) and SVIP-transfected BB30-HNC cells were injected into the 
left and right flank, respectively, of 10 mice. Tumor volume over time (left) and tumor weight upon sacrifice (right) are 
shown. Tumor growth and weight were analyzed using a 2-tailed Student’s t test. Data shown as mean ± SEM. *P < 
0.05; **P < 0.01; ***P < 0.001. ns, not significant.
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difference in cell viability, measured by the SRB assay, between SVIP- and empty vector–transfected BB30-
HNC cells upon the use of  proteasome (bortezomib) (24), VCP/p97 (Eeyarestatin I and NMS-873) (25, 26), 
and Hsp90 (17-AAG and IPI-504) (27, 28) inhibitors (Supplemental Figure 4). However, the recovery of  SVIP 
expression in these cancer cells rendered them sensitive to thapsigargin (Figure 3F), a specific inhibitor of  the 
sarcoplasmic/ER Ca2+-ATPase (SERCA) (29). SERCA is responsible for calcium transference from the cyto-
sol to ER, and low levels of  calcium in the ER are associated with the loss of  activity of  calcium-dependent 
ER chaperones, such as calnexin and calreticulin, leading to the accumulation of  unfolded proteins (30, 31). 
These results are further evidence of  the role of  SVIP in inducing ER stress in cancer cells, and suggest that 
they could be targeted by compounds that disturb calcium homeostasis.
SVIP induces a metabolic shift from aerobic glycolysis to mitochondrial respiration. The impact of  SVIP on ER 
stress is linked to the role of  SVIP as an endogenous inhibitor of  ERAD (14). The ER is a central organelle 
for the synthesis and maturation of  proteins, and the ERAD pathway eliminates misfolded and unassembled 
polypeptides, in addition to physiologically regulating the abundance of  normal protein in the ER (4, 6). In 
Figure 3. Restoration of SVIP activity in cancer cells provokes ER stress. (A) Electron 
microscopy images show ER sections (white arrows) in empty vector–transfected BB30-HNC 
cells (BB30-HNC EV). Recovery of SVIP expression (BB30-HNC SVIP) induces ER dilation 
with the characteristic intracellular vacuoles derived from the ER (red arrows). The induction 
of double-membrane autophagosomes was also observed (black arrows). All scale bars: 1 
μm. (B) Representative Western blots of various proteins associated with ER stress such as 
UPR pathway (IRE1α, PERK, and phosphorylation of eIF2α) and protein folding assistance 
(PDI and ERO1-Lα) in SVIP-expressing BB30-HNC and SVIP-depleted Ca9-22 cell lines. (C) 
Representative Western blots of autophagic markers after SVIP recovery in BB30-HNC cells. 
(D) Representative Western blots of PARP and caspase 3 in SVIP-transfected BB30-HNC 
cells. (E) Representative Western blot of cell cycle arrest marker p21. All Western blots in B–E 
were performed in triplicate. (F) SRB assay to determine the growth inhibitory effect of the 
SERCA inhibitor thapsigargin in SVIP-silenced and SVIP-restored BB30-HNC cells. This graph 
is representative of 3 independent experiments. Each data point represents mean ± SD of 
3 replicates. Statistical differences were determined by adjusting the curve to a third-grade 
polynomial equation followed by extra sum-of-squares F test. **P < 0.01.
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this regard, the inhibition of  ERAD by the restoration of  SVIP expression in BB30-HNC cancer cells was 
accompanied by the accumulation of  polyubiquitinated proteins that are not degraded (Figure 4A). However, 
the set of  proteins that are controlled in particular by the SVIP-mediated inhibition of  ERAD have not been 
characterized or studied in the context of  cancer cells. We decided to address this issue by taking advantage 
of  our discovery of  SVIP epigenetic loss in transformed cells. We carried out stable isotopic labeling of  amino 
acids in cell culture (SILAC) in empty vector–transfected BB30-HNC cells in comparison with SVIP stably 
transfected BB30-HNC cells to identify proteins whose expression levels were SVIP dependent (Figure 4B). 
At the level of  resolution used in the SILAC assay, we observed 124 proteins with significantly different 
expression upon SVIP transfection in BB30-HNC cells (Supplemental Table 1). Most proteins (88%, 110 of  
124) showed upregulation upon the recovery of  SVIP expression, whereas the other 12% (14 of  124) were 
downregulated (Figure 4C and Supplemental Table 1). These results fit with the idea that the restoration of  
SVIP, due to its activity as an ERAD inhibitor, enhances protein levels. In this regard, we found that SVIP 
transfection upregulated the protein levels of  known ERAD targets (32) without increasing the levels of  the 
corresponding RNA transcripts (Figure 4D), as expected. We performed a Gene Ontology (GO) analysis to 
classify the 110 proteins upregulated upon SVIP transfection in all biological process categories. Metabolic 
process (GO: 0008152) was the third category represented from the most general classification of  biological 
process, according to the GO Consortium (33). However, most importantly, a deeper analysis of  all biological 
processes in GO revealed that 9 out of  10 more significantly overrepresented categories belonged to the met-
abolic process subgroup (Figure 4E), particularly for components of  mitochondrial metabolism. We selected 
illustrative targets of  these pathways identified as upregulated by SVIP in the SILAC approach (Supplemen-
tal Table 1), such as SUCLG2 (tricarboxylic acid cycle), NDUFB8 (oxidative phosphorylation), MT-CO2 
(oxidative phosphorylation), and SLC25A5 (mitochondrial carrier) for Western blot and qPCR assays. We 
confirmed that their SVIP-mediated upregulation occurred at the protein level and was not associated with a 
difference in RNA levels (Figure 4F), consistent with the proposed role of  SVIP as an ERAD inhibitor.
Among the few downregulated proteins observed following SVIP transfection (Supplemental Table 
1), we found the glucose transporter 1 (GLUT1), also known as SLC2A1, a glucose transporter that 
constitutes a rate-limiting step of  glucose metabolism and whose overexpression in tumors is associated 
with increased aerobic glycolysis (16, 34). Western blot confirmed its loss in SVIP-transfected BB30-
HNC (Figure 4G), BHY (Supplemental Figure 5A), and Ca-Ski (Supplemental Figure 5A) cells, but we 
also found decreased levels of  its transcript (Figure 4G and Supplemental Figure 5A), so a compensatory 
mechanism associated with the emergence of  mitochondrial metabolism proteins upon SVIP restoration 
might occur instead of  being a direct effect of  SVIP on its protein degradation. In this regard, we found 
that SVIP promoter CpG island hypermethylation was also associated with the downregulation of  the 
GLUT1 transcript in the Sanger panel of  cancer cell lines (15) (Figure 4H), being more significant for 
the 4 tumor types more methylated at the SVIP locus (Figure 4H). SVIP downregulation was also asso-
ciated with low levels of  the GLUT1 transcript in the same panel of  cell lines (Supplemental Figure 5B). 
SVIP methylation–associated silencing is also associated with high levels of  expression of  the glycolytic 
enzyme hexokinase 1 and low levels of  the uncoupling mitochondrial enzyme UCP2 (Supplemental 
Figure 5C). Overall, the picture that emerges indicates that SVIP reintroduction caused an enrichment of  
mitochondrial metabolism compared with SVIP epigenetically deficient cancer cells.
The scenario described above made us wonder whether SVIP hypermethylation–associated silencing 
could mediate the common metabolic shift of  cancer cells that move away from oxidative phosphorylation 
toward aerobic glycolysis, a phenotype known as the Warburg effect (34, 35). To address this question, we per-
formed a comprehensive set of  biochemical and cellular assays. We found that SVIP-transfected BB30-HNC 
cells experienced reduced cellular glucose uptake in comparison with empty vector–transfected cells (Figure 
5A), a finding that relates to the aforementioned SVIP-associated downregulation of  GLUT1. In this regard, 
a common characteristic of  tumoral cells is the enhanced dependence on glucose to boost aerobic glycolysis, 
which produces a large amount of  lactate. We found that the restoration of  SVIP activity in the epigeneti-
cally silenced cells decreased lactate levels (Figure 5B), suggesting that the glycolytic pathway is depleted. In 
addition, SVIP stably transfected cells exhibited a higher basal oxygen consumption rate (OCR), and had 
enhanced ATP-linked OCR and maximal OCR compared with empty vector–transfected BB30-HNC cells 
(Figure 5C), indicating a shift from aerobic glycolysis to oxidative phosphorylation on SVIP recovery. As fur-
ther evidence of  this, ATP levels were higher in the SVIP-transfected BB30-HNC cells (Figure 5D). MitoSox 
median fluorescence intensity (MFI) determined by flow cytometry showed an increase of  mitochondrial 
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Figure 4. Recovery of SVIP expression in cancer cells upregulates mitochondrial metabolism proteins and downregulates a glucose uptake protein. (A) Rep-
resentative Western blot showing the accumulation of polyubiquitinated proteins after SVIP recovery in BB30-HNC cells. (B) Workflow of the SILAC developed 
to detect protein changes in BB30-HNC cells upon SVIP transfection. (C) Volcano plot summarizes the SILAC results. One hundred ten proteins were significantly 
upregulated (P < 0.05) (red dots), whereas only 14 were downregulated (blue dots). (D) Validation by Western blot (left) of the upregulation of 4 ERAD target 
proteins upon transfection of the ERAD inhibitor SVIP. mRNA levels determined by qPCR (right) do not change upon SVIP restoration. (E) Top: Number of proteins 
represented in general gene clusters of Biological Process Gene Ontology enriched with FDR < 0.05. Bottom: Number of proteins represented in top 10 nonre-
dundant clusters of Biological Process Gene Ontology according to their significance (FDR). Colors depict the level 1 Biological Process category in which they are 
included according to the top panel of Figure 4D. (F) Western blot (left) shows upregulation of 4 mitochondrial metabolism proteins upon recovery of SVIP in 
BB30-HNC cells. mRNA levels determined by qPCR (right) do not change upon SVIP transfection. (G) Recovery of SVIP activity causes downregulation of GLUT1 at 
the protein (left) and mRNA (right) levels, as determined by Western blot and qPCR, respectively. (H) SVIP promoter hypermethylation is significantly associated 
with loss of the GLUT1 transcript in the Sanger panel of cancer cell lines (n = 862) (left); this correlation was stronger when considering only head and neck cancer, 
esophageal, cervical, and hematological cell lines (n = 235) (right). Two-tailed Mann-Whitney U test was performed to compare GLUT1 expression between methyl-
ated and unmethylated cell lines. qPCRs were analyzed using 2-tailed Student’s t test, and are represented as the mean of triplicates. All Western blots in panels 
A, D, F, and G were performed in triplicate. *P < 0.05; **P < 0.01. ns, not significant.
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ROS upon SVIP restoration (Figure 5E). MitoTracker MFI probe revealed an increase in mitochondrial mass 
(Figure 5F). Importantly, SVIP-transfected BHY and Ca-Ski mimicked the phenotype observed for SVIP 
recovery in BB30-HNC cells; SVIP restoration enhanced ATP levels (Supplemental Figure 5D) and increased 
mitochondrial mass determined by the MitoTracker probe (Supplemental Figure 5E). Finally, to further elu-
cidate the identified SVIP metabolic shift, we performed isotopologue enrichment analysis using uniformly 
labeled glucose (U-13C6-glucose), followed by mass spectrometric quantification. This approach demonstrated, 
again, the greater use of  the tricarboxylic acid (TCA) cycle upon SVIP restoration. The detailed isotopologue 
enrichment analysis also showed an increase in carbon contribution to succinate and citrate in SVIP-transfect-
ed cells. Major proportions of  M4 and M6 citrate and M2 and M4 succinate in SVIP-transfected cells revealed 
a higher glucose flux into the mitochondria (Figure 5G).
Our greatest interest was whether the metabolic dependence of SVIP epigenetically deficient cancer cells on 
glucose, described above, could be exploited for therapeutic purposes. To address this, we first examined whether 
SVIP expression levels affected cancer cell glucose-dependent growth. We found that BB30-HNC empty vector–
transfected cells were unable to grow in media with a low glucose content, but the recovery of SVIP expression 
allowed the growth of these cells in the glucose-depleted context (Figure 5H). We then continued the study in 
a pharmacological context using Bay-876, a recently developed specific inhibitor for GLUT1 (36), the protein 
responsible for glucose uptake that we found upregulated in SVIP epigenetically deficient cells (Figure 4G). 
Bay-876 displays high selectivity for GLUT1 in comparison with other glucose transporters such as GLUT2, 
GLUT3, and GLUT4 (36). We first assessed in our panel of cancer cell lines whether DNA methylation–asso-
ciated silencing of SVIP was associated with different sensitivity to Bay-876. The determination of the corre-
sponding IC50 values, according to the SRB assay for cell viability, showed that SVIP epigenetically deficient 
cancer cells were significantly more sensitive to the specific GLUT1 inhibitor than the SVIP-unmethylated cell 
lines (Fisher’s exact test, P < 0.05) (Figure 5I). Furthermore, the restoration of SVIP activity in the epigenetically 
deficient cancer cells rendered resistance to Bay-876 (Figure 5J) in comparison with the empty vector–transfect-
ed cells, which were very sensitive to the small-drug-mediated blockage of glucose uptake. We translated these 
results to the in vivo setting where we assessed the effect of Bay-876 in subcutaneous xenografted tumors in 
nude mice. No evident general toxicity was observed in these mice, in agreement with other previously analyzed 
animal models such as rat and dog (36). Importantly, we found that tumors derived from SVIP-hypermethylated 
cancer cells were significantly sensitive to growth inhibition upon Bay-876 use, whereas tumors derived from 
cancer cells where we had restored SVIP expression showed resistance to the compound (Figure 5K).
Overall, the data indicate that cancer cells harboring DNA methylation–associated loss of  SVIP are 
dependent on glucose and aerobic glycolysis to obtain the cellular energy necessary for their survival, 
whereas SVIP restoration promotes the use of  the homeostatic mitochondrial respiration. Interestingly, 
the extremely high dependence on glucose of  those cancer cells with epigenetic loss of  SVIP pinpoints a 
possible therapeutic opportunity for the use of  glucose uptake blockers in the management of  these tumors.
SVIP epigenetic loss in primary tumors is associated with GLUT1 upregulation and poor clinical outcome. The 
presence of  SVIP promoter CpG island hypermethylation was not confined to established cancer cell lines, 
but was also observed in primary human malignancies. Data-mining of  the set of  primary human tumors 
from The Cancer Genome Atlas (TCGA) project (https://cancergenome.nih.gov/), interrogated by the same 
DNA methylation microarray used herein (37), demonstrated the occurrence of  5′-end CpG island hyper-
methylation of  the SVIP gene in a wide spectrum of tumor types that was similar to the profile observed in the 
cancer cell line data (Figure 6A). In this regard, SVIP CpG island promoter hypermethylation was frequently 
found in head and neck (37%, 184 of  496), cervical (19%, 60 of  309), and esophageal (10%, 18 of  183) tumors 
(Figure 6A). As we also studied the cancer cell lines, we were able to compare the described TCGA profile 
of  SVIP CpG island methylation with the available RNA data. We found that SVIP CpG island promoter 
hypermethylation was associated with downregulation of  its transcript for the described tumor types (Figure 
6B), further reinforcing the link between aberrant DNA methylation and transcriptional inactivation of  the 
gene. As it occurred in the in vitro models, SVIP downregulation was associated with the overexpression of  
ER stress markers such as XBP1 and DERL3 (Supplemental Figure 6A). Interestingly, as previously noted in 
the cancer cell lines (Figure 4G), SVIP CpG island hypermethylation in the TCGA primary tumors was also 
associated with overexpression of  the GLUT1 transcript (Figure 6C). SVIP downregulation is also associated 
with low levels of  GLUT1 (Supplemental Figure 6B), the glycolytic enzyme HK1, and the mitochondrial 
protein UCP2 (Supplemental Figure 6C) among the TCGA samples. These results highlight the connection 
between SVIP epigenetic inactivation and glycolysis dependence.
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Figure 5. Restoration of SVIP expression in transformed cells shifts an aerobic glycolysis phenotype to homeostatic mitochondrial metabolism. Enzymatic 
determination of (A) glucose uptake and (B) lactate release normalized with respect to protein concentration in empty vector– and SVIP-transfected BB30-HNC 
cells. Graphs are representative of 3 independent experiments. Data were analyzed through 2-tailed Student’s t test. (C) Oxygen consumption rate (OCR) nor-
malized with respect to protein concentration of empty vector– and SVIP-transfected BB30-HNC cells under basal conditions (Basal), after oligomycin treatment 
(ATP-linked), and after FCCP injection (Maximal OCR). This graph is representative of 2 independent experiments, each with 5 technical replicates. (D) ATP 
concentration determination in empty vector– and SVIP-transfected BB30-HNC cells. Graph is representative of 3 independent experiments. (E) MitoSox median 
fluorescence intensity (MFI) was determined by flow cytometry. Nine replicates of 4 independent experiments are plotted. (F) MitoTracker MFI was determined by 
flow cytometry. Mean ± SD of a representative experiment is shown. (G) 13C-citrate and 13C-succinate isotopologue distribution after 24-hour exposure to 25 mM 
13C6-glucose. (H) BB30-HNC cell growth in 5 mM low-glucose medium. Graph is representative of 3 independent experiments. (I) SRB assays to determine cell via-
bility upon the use of Bay-876 (GLUT1 inhibitor) of 4 SVIP-unmethylated and -expressing cell lines (green) against 5 cell lines with SVIP hypermethylation–asso-
ciated silencing (red). (J) SRB assay shows that empty vector–transfected cells with SVIP epigenetic loss are significantly more sensitive to growth inhibition by 
Bay-876 treatment than are cancer cells with transfection-mediated recovery of SVIP expression. Graph is representative of 3 independent experiments. Statisti-
cal differences were determined by Student’s t test at the highest dose. (K) Growth inhibition of empty vector– and SVIP-transfected BB30-HNC cells in an in vivo 
subcutaneous mouse model was measured by tumor volume time course (left) and final tumor weight (right). Statistical differences in I and K were determined 
by adjusting the curves to third-grade polynomial equations followed by the extra sum-of-squares F test. *P < 0.5, **P < 0.01. ns, not significant.
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Finally, we wondered whether SVIP hypermethylation was of  any prognostic value with respect to 
the tumor suppressor capacity of  the protein, described above. To address this question, we compared 
the SVIP methylation status of  the primary head and neck tumors derived from TCGA with the avail-
able clinicopathological data (n = 282 samples), being the tumor type that most often experiences SVIP 
epigenetic inactivation (Figure 1A and Figure 6A). SVIP hypermethylation was associated with shorter 
disease-free survival (DFS) (log-rank; P = 0.024; hazard ratio [HR] = 1.65, 95% CI = 1.07–2.55) and worse 
overall survival (OS) (log-rank; P = 0.020; HR = 1.66, 95% CI = 1.08–2.57) in the head and neck cancer 
TCGA cohort (Figure 6D). Low SVIP expression was also associated with shorter DFS and worse OS 
(Supplemental Figure 6D), but GLUT1 expression did not associate with clinical outcome (Supplemental 
Figure 6E). Low SVIP expression was also associated with high expression of  the proliferation marker 
CCND1 (Supplemental Figure 6F). We did not find any associations between SVIP hypermethylation and 
the clinicopathological variables, except the histological classification, where SVIP hypermethylation was 
more common in head and neck carcinomas of  the squamous type (Supplemental Table 2). Furthermore, 
multivariate Cox regression analysis showed that SVIP hypermethylation was an independent predictor of  
shorter OS (HR = 1.61, P = 0.034; 95% CI = 1.04–2.51), in comparison with all other patient character-
istics, for the interrogated TCGA cohort of  head and neck cancer cases (Figure 6E). This implies that the 
epigenetic inactivation of  SVIP is a potential prognostic marker of  poor outcome for these malignancies.
Discussion
Cancer cells must overcome intracellular proteotoxic and metabolic stress, in addition to a hostile micro-
environment, to survive and proliferate. To adapt, transformed cells rely on hijacking the protein quality 
controls of  the ER, such as the adequate protein folding, the UPR, and the ERAD pathways. The latter net-
work, which has targets such as the tumor suppressor p53 (38), not only acts as a quality control mechanism 
that clears the ER of  unfolded proteins, but also regulates protein abundance (6, 39). In the current study, 
we have shown that a major mechanism used by common human tumors to influence the ERAD pathway 
occurs by promoter CpG island hypermethylation–associated silencing of  the ERAD inhibitor SVIP. The 
epigenetic loss of  this interactor of  AAA-ATPase VCP/p97, the enzyme responsible for retrotranslocation 
of  ERAD substrates across the ER membrane, is an effective way of  dealing with potentially excessive 
ER stress in the tumor types examined here. Restoration of  the SVIP protein induces major ER stress that 
blocks the growth of  these cancer cells, rendering them sensitive to drugs that lead to the accumulation of  
unfolded proteins such as SERCA inhibitors (29–31). Related to its ERAD inhibitor role, we observed that 
the recovery of  SVIP expression induced an increase in the expression levels of  many proteins. Interest-
ingly, many of  the proteins that become upregulated upon SVIP activation are required for mitochondrial 
metabolism, suggesting an important role for SVIP in the regulation of  cancer cell metabolism.
One of  the most common traits of  human tumors is the presence of  the Warburg effect (34, 35), charac-
terized by aerobic glycolysis. This metabolic phenotype is characterized, among other features, by increased 
glucose uptake and lactate production regardless of  oxygen concentration, an enhanced rate of  glycolysis, 
and a reduced level of  oxidative phosphorylation via the tricarboxylic acid (TCA) cycle (34, 35). Although 
the energetic production of  aerobic glycolysis is much lower than that of  oxidative phosphorylation, this shift 
seems to be positively selected in cancer cells due to its production of  growth-promoting glucose metabolites 
and enhanced nonoxidative ATP generation (40). Cancer cells come to express the Warbug effect by acquiring 
various genetic and epigenetic changes (34, 35, 40). Our results indicate that SVIP epigenetic silencing is a fre-
quent method by which the tumor types considered accomplish that goal. Cancer cells with SVIP hypermeth-
ylation–associated silencing are characterized by increased glucose uptake and lactate production, decreased 
mitochondrial mass and activity, and a greater dependence on glucose. However, the restoration of  the SVIP 
protein reverts the Warburg phenotype to one of  physiological mitochondrial respiration.
Most importantly from the translational standpoint, cancer cells carrying the SVIP epigenetic defect 
have high levels of  GLUT1, the protein responsible for the intracellular uptake of  glucose, in cell lines 
and primary tumors, whereas in vitro these cells are highly dependent on glucose for their growth. 
Remarkably, tumoral cells with SVIP hypermethylation are very sensitive to a newly designed small 
molecule, Bay-876, that is a specific inhibitor of  GLUT1 (36), whereas the recovery of  SVIP expres-
sion produces resistance to this drug. These findings could be extremely significant in the clinical con-
text, because human tumors that overexpress GLUT1 are usually associated with the poor outcome of  
patients (41, 42). In this regard, we have noted the same phenomenon, whereby primary tumors with the 
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SVIP epigenetic alteration have the shortest OS. These observations justify the increasing efforts to find 
small-molecule inhibitors of  GLUT1 (42) and to explore the potential therapeutic benefit of  the block-
age of  this transporter. The appropriate selection of  the tumors treated with the GLUT1 inhibitor could 
be critical to avoiding excessive toxicity because this protein is expressed in all normal tissues in order 
to maintain the basal glucose supply (43). Patients with tumors exhibiting SVIP epigenetic loss and an 
associated “addiction” to aerobic glycolysis, glucose, and GLUT1, are likely to respond better in future 
clinical trials designed to validate the genuine therapeutic benefits of  these types of  drugs.
Figure 6. SVIP epigenetic inactivation in human primary tumors and its association with poor clinical outcome. (A) Percentage of SVIP methylation in 
the TCGA data set of primary tumors by cancer type. Samples were considered hypermethylated with a β value higher than 0.33. (B) SVIP promoter CpG 
island methylation is associated with the loss of the SVIP transcript among head and neck, cervical, and esophageal primary tumors in the TCGA data set. 
Two-tailed Mann-Whitney U test was performed. (C) SVIP hypermethylation is associated with a high level of expression of the GLUT1 transcript among 
head and neck, cervical, and esophageal primary tumors in the TCGA data set. (D) Kaplan-Meier analysis of DFS (top) and OS (below) by SVIP methyla-
tion status in head and neck primary tumors of the TCGA data set. The P value corresponds to the log-rank test. Results of the univariate Cox regression 
analysis are represented by the hazard ratio (HR) and 95% confidence interval (CI). (E) Multivariate Cox regression analysis of OS, represented by a forest 
plot, taking into account the clinical characteristics of the TCGA cohort of head and neck cancer patients. In multivariate analyses, significant covariates 
are considered independent prognostic factors of clinical outcome; this was the case for SVIP methylation. *P < 0.05; **P < 0.01.
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Methods
Cell lines and primary tumor samples. Cancer cell lines were purchased from the American Type Culture Col-
lection (ATCC) (Ca-Ski, HeLa, and SW756), the German Collection of  Microorganisms and Cell Cultures 
(DSMZ) (BHY, COLO-680N and KYSE-180), and Sigma-Aldrich (OACM 5.1C). Lb771-HNC, Ca9-22, 
and BB30-HNC were kindly provided by the Sanger Institute. The head and neck cancer cell lines were cul-
tured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) 
and 1% penicillin/streptomycin antibiotic at 37°C and 5% CO2. Cervical and esophageal cell lines were 
cultured in Roswell Park Memorial Institute (RPMI1640) medium supplemented with 10% FBS and 1% 
penicillin/streptomycin antibiotic at 37°C and 5% CO2. DNA methylation and clinical information about 
patients with primary tumors was obtained from the TCGA database by using the cgds-R package and the 
cBioPortal website (https://www.cbioportal.org/).
DNA methylation analysis. DNA methylation profiles were obtained by bisulfite genomic sequenc-
ing. CpG islands were identified in silico using Methyl Primer Express v1.0 (Applied Biosystems). 
Genomic DNA was converted using the EZ DNA Methylation-Gold Kit (ZYMO Research). Bisulfite 
PCR products were transformed into competent bacteria. At least 8 clones were sequenced to calcu-
late the methylation frequency. Sequence reads were aligned using BioEdit software and promoter 
methylation was represented using BSMap software. Bisulfite sequencing primers are listed in the 
Key Resources Table in the supplemental material. The DNA methylation microarray used was the 
Infinium HumanMethylation450 BeadChip (Illumina). In silico DNA methylation analysis of  VCP/
p97, SELENOS, SYVN1, SVIP, and AMFR/GP78 was performed using CpG sites located in the cor-
responding 5′-end regulatory regions (listed in Dataset 1). The threshold to define “methylated” was 
an average of  the interrogated CpG β values ≥ 0.66.
Expression analysis. Total RNA was extracted from cell lines using the cell lysate program for the 
Maxwell 16 instrument (Promega). RNA (2 μg) was retrotranscribed using GoScript (Promega). qPCR 
reactions were performed using SYBR Green PCR Master Mix (Thermo Fisher Scientific) in a Quant-
Studio 5 Real-Time PCR System (Thermo Fisher Scientific). Data were normalized using GAPDH as an 
endogenous control. qPCR primers are listed in the Key Resources Table in the supplemental material. 
Total protein extracts were obtained using RIPA buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM 
Na2EDTA, 1 mM EGTA, 1% NP-40) and quantified using the DC Protein Assay (Bio-Rad). Protein 
levels were analyzed by Western blot using β-actin (ACTB), α-tubulin (TUBA), or lamin B1 (LMNB1) 
as the loading control. Specific primary and secondary antibodies against target proteins are listed in the 
Key Resources Table in the supplemental material.
Modulation of  in vitro SVIP expression. The SVIP cDNA sequence was subcloned into the pLVX-IRES-Zs-
Green 1 expression vector (Clontech). The forward primer contained a Kozak consensus sequence, which pro-
motes flexible transcript translation. Four shRNAs designed with rnaidesigner (Thermo Fisher Scientific) were 
subcloned into the pLVX-shRNA2 vector. Empty pLVX-IRES-ZsGreen 1 and shRNA against the MSS2 yeast 
mRNA (not present in mammals) were used as a control in overexpression and depletion models, respectively. 
Plasmids were transfected in HEK-293T cells using jetPRIME Transfection Reagent (Polyplus Transfection), 
together with psPAX2 (Addgene) and pMD2.G (Addgene) packaging plasmids. After 72 hours, the lentiviral 
supernatant medium was collected and 0.45-μm filtered. Cell lines were cultured in the medium containing 
the appropriate virus for 24 hours. After 5 passages, ZsGreen 1–positive cells were sorted by FACS.
Imaging. For TEM, cancer cells were fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer, post-
fixed in 1.5% osmium tetroxide, and processed using the tEPON 812 embedding Kit (Tousimis). The 
ultrathin sections, stained with uranyl acetate and lead citrate, were assessed at 80 kV with a JEM-1011 
(JEOL) transmission electron microscope. For senescence-associated β-galactosidase staining, BB30-
HNC cells were fixed with 2% v/v paraformaldehyde and 0.2% v/v glutaraldehyde and stained (40 mM 
citric acid phosphate pH 6.0, 150 mM NaCl, 5 mM K3Fe[CN]6, K4Fe[CN]6, 2 mM MgCl2, and 1 mg/ml 
X-Gal solution) for quantifying senescent cells.
Cell viability and drug-dose response assays. Cell viability was assessed by the SRB assay. Cells per well were 
seeded at 1,000 cells/well in 96-well plates. On 7 consecutive days, cells were fixed with 10% trichloroacetic 
acid, washed, then stained with the SRB dye. Cell viability was assessed by measuring absorbance at 540 nm. 
For the glucose-dependent cell viability assay, 2,000 cells per well were seeded in 96-well plates and grown in 
glucose-, pyruvate-, and glutamine-free media supplemented with dialyzed FBS, 1 mg/ml glucose, and 4 mM 
glutamine. Medium was changed every 24 hours to avoid nutrient depletion. The SRB assay was carried out 
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at 0, 24, 48, and 72 hours. For drug dose-response assays, 5,000 cells per well were plated in 96-well plates and 
treated with different doses of  the appropriate drug after overnight cell adherence. The SRB assay was per-
formed after 96 hours. Bortezomib was purchased from LC Laboratories. 17-AAG, Eeyarestatin I, Bay-876, 
and thapsigargin were purchased from Sigma-Aldrich. IPI-504 was purchased from Medchem.
In vivo experiments. Empty vector–transfected or SVIP-transfected BB30-HNC cells (3.5 × 106) were inject-
ed into the left and right flanks, respectively, of  nude male mice. Tumor growth was monitored every 2 days 
by measuring its width (W) and length (L). Tumor volume, V, was estimated using the formula V = π/6 × L × 
W2. Mice were sacrificed 80 days after injection and their tumor weight measured. Bay-876 was administered 
orally at 4 mg/kg dissolved in 1:9 NMP/PEG (1-methyl-2-pyrolidinone/poly [ethylene glycol] 300).
Cytometry analyses. Mitochondrial ROS were measured using red MitoSox probe (Thermo Fisher Sci-
entific). Mitochondrial mass was measured using deep-red MitoTracker probe (Thermo Fisher Scientific). 
Cultured cells were incubated with the aforementioned probe for 30 minutes and then analyzed with a 
FACSCalibur (Beckton Dickinson).
SILAC labeling and liquid chromatography–mass spectrometry analysis. SILAC labeling was performed using 
SILAC Lys(8) Arg(10) Kit medium (Silantes). Empty vector– and SVIP-transfected BB30-HNC cells were 
grown for 10 days in heavy medium [Lys(8), Arg(10)] or light medium [Lys(0), Arg(0)]. After labeling, protein 
was extracted by using RIPA buffer. Protein levels were quantified by Lowry and mixed at a 1:1 ratio. Samples 
were further processed by the FASP method followed by alkylation with iodoacetamide and overnight diges-
tion by Lys-C and trypsin at 37°C in 50 mM ammonium bicarbonate. Peptide mixes were analyzed using an 
Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific) coupled to an EasyLC (Thermo Fisher 
Scientific). All data were acquired with Xcalibur software v3.0.63. The Proteome Discoverer software suite 
(v2.0, Thermo Fisher Scientific) and the Mascot search engine (v2.5, Matrix Science) were used to identify 
and quantify peptides. Samples were searched against a Swiss-Prot database containing entries corresponding 
to Human (https://www.uniprot.org/peptidesearch/, April 2016 version), a list of  common contaminants, 
and all the corresponding decoy entries. Resulting data files were filtered for FDR < 1%.
Gene functional enrichment analysis. Gene sets were used to analyze gene set overrepresentation in 
the GO biological processes included in the PANTHER web service (http://www.pantherdb.org/). The 
general categories and top gene clusters resulting from the hypergeometric test with an FDR-adjusted P 
value < 0.05 were subsequently considered.
Metabolic determinations. Oxygen consumption and pH variation were determined using an XF24 extracel-
lular flux analyzer (Seahorse Bioscience). Those variables were measured under routine conditions (DMEM 
plus 5.5 mM glucose) and after the sequential addition of  1 μg/ml oligomycin (Complex V inhibitor), 1.5 
μM FCCP, and 0.1 μM rotenone and antimycin A. All substrates, uncouplers, and inhibitors were purchased 
from Sigma-Aldrich. Concentrations of  glucose and lactate in growth medium were determined by enzymatic 
assays. After overnight cell adherence, medium was collected and replaced every 24 hours. Glucose concen-
tration was calculated by coupling hexokinase and glucose-6-phosphate dehydrogenase enzymatic reactions. 
Lactate concentration was determined by its conversion to pyruvate by LDH in the presence of  hydrazine. 
In all cases, absorbance at 340 nm was measured using a Cobas Mira Chemical Analyzer (Roche) to assess 
NADH concentration, which is directly proportional to the given metabolite concentration. Glucose and 
lactate concentrations at 24, 48, and 72 hours were compared with the concentration at the start time to 
assess consumption and production, respectively. Data were normalized by SRB assay of  the cultured cells. 
ATP production was calculated using CellTiter-Glo (Promega) according to the manufacturer’s indications. 
Absolute ATP concentration was calculated using the dATP standard curve following the Beer-Lambert law.
Metabolic flux analysis. Cells were cultured for 24 hours in the presence of  fully labeled glucose (13C6-glu-
cose, Sigma-Aldrich). Then, cell pellets were scraped, collected, and frozen. Briefly, cell pellets were resus-
pended with 450 μl of  cold methanol/water (8:1, v/v) containing 13C-glycerol (5 ppm) as internal standard. 
Metabolite lysates were purified with 3 rounds of  liquid nitrogen immersion and sonication, followed by 1 
hour in ice before centrifugation (5000 g, 15 minutes at 4°C). Samples were dried under a stream of  N2 gas 
and lyophilized before chemical derivatization with 12 μl methoxyamine in pyridine (40 μg/μl) for 45 min-
utes at 60°C. Samples were also sialylated using 8 μl N-methyl-N-trimethylsilyltrifluoroacetamide with 1% 
trimethylchlorosilane (Thermo Fisher Scientific) for 30 minutes at 60°C to increase the volatility of  metab-
olites.  A 7890 GC system coupled to a 7000 QqQ mass spectrometer (Agilent Technologies) was used for 
isotopologue determination. Derivatized samples (1 μl) were injected into the gas chromatograph system 
with a split inlet equipped with a J&W Scientific DB5−MS+DG stationary phase column (30 mm × 0.25 
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mm i.d., 0.1 μm film, Agilent Technologies). Helium was used as the carrier gas. Metabolites were ionized 
using positive chemical ionization (CI) with isobutene as reagent gas. Mass spectral data on the 7000 QqQ 
were acquired in scan mode, monitoring selected ion clusters of  the various metabolites.
Statistics. The associations between variables were assessed by Welch’s t test, Student’s t test, the Wilcox-
on paired test, or Spearman’s correlation as appropriate. Kaplan-Meier plots and log-rank tests were used to 
estimate OS. Statistical analyses were carried out with IBM SPSS for Windows and GraphPad Prism 5 for 
Windows. Values of  P < 0.05 were considered statistically significant. All statistical tests were 2-sided.
Study approval. All animal studies were approved by and conducted in accordance with the guidelines 
established by the IDIBELL Animal Research Ethics Committee (procedure number 3880).
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